Orthopediatrics (NASDAQ:KIDS) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.
According to Zacks, “OrthoPediatrics Corp. is a medical device company. It markets surgical systems for trauma and deformity, bone fractures and reconstruction procedures. OrthoPediatrics Corp. is based in NEW YORK. “
Other equities research analysts have also issued reports about the stock. BTIG Research reiterated a “buy” rating and set a $44.00 target price on shares of Orthopediatrics in a research note on Monday, April 29th. BidaskClub upgraded shares of Orthopediatrics from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Finally, JMP Securities initiated coverage on shares of Orthopediatrics in a research note on Wednesday, February 20th. They set an “outperform” rating and a $44.00 target price for the company. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $41.00.
KIDS stock opened at $41.02 on Tuesday. The company has a market capitalization of $594.02 million, a P/E ratio of -42.73 and a beta of 0.04. Orthopediatrics has a 12-month low of $18.77 and a 12-month high of $47.82. The company has a current ratio of 10.54, a quick ratio of 7.77 and a debt-to-equity ratio of 0.26.
Orthopediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.04). The business had revenue of $14.66 million during the quarter, compared to the consensus estimate of $14.67 million. Orthopediatrics had a negative net margin of 16.71% and a negative return on equity of 18.32%. As a group, analysts forecast that Orthopediatrics will post -0.43 EPS for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. boosted its position in shares of Orthopediatrics by 18.8% during the 3rd quarter. BlackRock Inc. now owns 405,478 shares of the company’s stock valued at $14,856,000 after purchasing an additional 64,282 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Orthopediatrics by 20.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 70,225 shares of the company’s stock valued at $2,573,000 after purchasing an additional 11,931 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Orthopediatrics during the 3rd quarter valued at about $242,000. Vanguard Group Inc. boosted its position in shares of Orthopediatrics by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 319,553 shares of the company’s stock valued at $11,708,000 after purchasing an additional 28,073 shares in the last quarter. Finally, Vanguard Group Inc boosted its position in shares of Orthopediatrics by 9.6% during the 3rd quarter. Vanguard Group Inc now owns 319,553 shares of the company’s stock valued at $11,708,000 after purchasing an additional 28,073 shares in the last quarter. Institutional investors and hedge funds own 45.03% of the company’s stock.
Orthopediatrics Company Profile
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.
Featured Article: Net Margin
Get a free copy of the Zacks research report on Orthopediatrics (KIDS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com